← Back to Search

Monoclonal Antibodies

Epcoritamab for Lymphoma

Phase 2
Recruiting
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with "double-hit" or "triple-hit" DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations). Note: Other double-/triple-hit lymphomas are not eligible.
Relapsed or refractory disease and previously treated with at least 2 prior systemic antineoplastic therapies including at least 1 anti-CD20 monoclonal antibody-containing therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 months
Awards & highlights

Study Summary

This trial is being conducted to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL).

Who is the study for?
Adults with relapsed or refractory Diffuse Large B-Cell Lymphoma or Follicular Lymphoma, who have had at least two prior treatments including an anti-CD20 therapy. Participants must have adequate organ function and a performance status showing they can carry out daily activities with ease to moderate difficulty.Check my eligibility
What is being tested?
The trial is testing Epcoritamab, an experimental drug for certain aggressive lymphomas. Patients will receive increasing doses of the drug through skin injections in cycles lasting 28 days each, to determine its safety and monitor any adverse effects.See study design
What are the potential side effects?
Specific side effects are not listed but may include reactions at the injection site, general discomfort, changes in blood tests indicating organ function issues, and other symptoms that will be closely monitored by healthcare professionals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lymphoma is classified as 'double-hit' or 'triple-hit' DLBCL.
Select...
My condition has not improved after two cancer treatments, including one with anti-CD20.
Select...
My lymphoma shows up on scans and has at least one large tumor.
Select...
My lymphoma shows on scans with specific size tumors or nodes.
Select...
I am able to get out of my bed or chair and move around.
Select...
I have relapsed or refractory DLBCL or FL with CD20+ B-cells.
Select...
My lymphoma is classified as 'double-hit' or 'triple-hit' DLBCL.
Select...
My organs are working well.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events
Percentage of Participants Experiencing Grade 3 or Higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
Percentage of Participants Experiencing Grade 3 or Higher Neurotoxicity (Ntox) Events
Secondary outcome measures
Best Overall Response (BOR) Determined by Lugano 2014 Criteria Per Investigator Assessment
CR Determined by Lugano 2014 Criteria Per Investigator Assessment
Diversity Enriched Cohort: Duration of CR (DOCR)
+19 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Main Cohort: Epcoritamab Follicular Lymphoma (FL)Experimental Treatment1 Intervention
Participants with R/R FL will receive SC epcoritamab in 28 day cycles.
Group II: Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL)Experimental Treatment1 Intervention
Participants with relapsed or refractory (R/R) DLBCL will receive subcutaneous (SC) epcoritamab in 28 day cycles.
Group III: Diversity Enriched Cohort: Epcoritamab FLExperimental Treatment1 Intervention
Participants with R/R FL will receive SC epcoritamab in 28 day cycles.
Group IV: Diversity Enriched Cohort: Epcoritamab DLBCLExperimental Treatment1 Intervention
Participants with R/R DLBCL will receive SC epcoritamab in 28 day cycles.

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
950 Previous Clinical Trials
496,744 Total Patients Enrolled
GenmabIndustry Sponsor
56 Previous Clinical Trials
12,048 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
390 Previous Clinical Trials
141,535 Total Patients Enrolled

Media Library

Epcoritamab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05451810 — Phase 2
Non-Hodgkin's Lymphoma Research Study Groups: Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL), Main Cohort: Epcoritamab Follicular Lymphoma (FL), Diversity Enriched Cohort: Epcoritamab DLBCL, Diversity Enriched Cohort: Epcoritamab FL
Non-Hodgkin's Lymphoma Clinical Trial 2023: Epcoritamab Highlights & Side Effects. Trial Name: NCT05451810 — Phase 2
Epcoritamab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05451810 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are enrolled in this research study?

"Affirmative. Records on clinicaltrials.gov attest to the fact that this study, initially posted on August 17th 2022, is currently searching for participants. A total of 80 volunteers must be recruited from 45 different sites."

Answered by AI

What is the purpose of this research endeavor?

"The primary metric of success for this trial, assessed over a period stretching up to 3 months, is the proportion of participants experiencing Grade 3 or higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events. Secondary outcomes include median time to onset of CRS at Grade 3 intensity or above, rate of patients receiving interventions post first full dose of epcoritamab and percentage of any adverse events experienced by volunteers."

Answered by AI

Has the government greenlighted Epcoritamab for therapeutic implementation?

"Epcoritamab's safety level was rated at 2, as there is limited clinical evidence for its efficacy but extant information regarding its security."

Answered by AI

Does this experiment currently have room for more volunteers?

"Affirmative. According to the information on clinicaltrials.gov, this medical trial is actively searching for participants and has been since August 17th 2022 when the study was initially posted with its most recent edit occurring November 21st of that same year."

Answered by AI

What is the geographic scope of this research endeavor?

"Currently, this clinical trial is operating from 45 different medical centres. Participants can choose the closest site to them among Oklahoma City, San Antonio and Lebanon or any of the other 42 locations. This way they won't need to travel too far for their appointments."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
New Jersey
What site did they apply to?
Clinical Research Philadelphia, LLC
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
~123 spots leftby Aug 2027